Jazz Pharmaceuticals is edging back up toward a buy point after a breakout attempt last week fizzled. The Ireland-based Jazz (JAZZ) is just below the 176.46 entry of a cup-without-handle base. It briefly cleared the buy point Nov. 5 after a better-than-expected earnings report. Since then, the stock’s Accumulation/Distribution Rating has risen two notches, to B+ from B-, indicating improved demand from institutional investors.